Cargando…

Adherence to riluzole in patients with amyotrophic lateral sclerosis: an observational study

OBJECTIVE: Riluzole is the first drug approved to treat amyotrophic lateral sclerosis (ALS). Recently, an oral suspension (OS) of riluzole was made available. Thus, the aim of our study was to evaluate the adherence to 2 formulations of riluzole in patients with ALS. PATIENTS AND METHODS: We enrolle...

Descripción completa

Detalles Bibliográficos
Autores principales:	Introna, Alessandro, D’Errico, Eustachio, Modugno, Boris, Scarafino, Antonio, Fraddosio, Angela, Distaso, Eugenio, Tempesta, Irene, Mastronardi, Antonella, Simone, Isabella Laura
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5757977/ https://www.ncbi.nlm.nih.gov/pubmed/29379292 http://dx.doi.org/10.2147/NDT.S150550

Ejemplares similares

Motor-evoked potentials in amyotrophic lateral sclerosis: potential implications in detecting subclinical UMN involvement in lower motor neuron phenotype
por: Zoccolella, Stefano, et al.
Publicado: (2020)

Dysregulation of MicroRNAs and Target Genes Networks in Peripheral Blood of Patients With Sporadic Amyotrophic Lateral Sclerosis
por: Liguori, Maria, et al.
Publicado: (2018)

Magnetic resonance metrics to evaluate the effect of therapy in amyotrophic lateral sclerosis: the experience with edaravone
por: Distaso, Eugenio, et al.
Publicado: (2021)

Corrigendum: Dysregulation of MicroRNAs and Target Genes Networks in Peripheral Blood of Patients With Sporadic Amyotrophic Lateral Sclerosis
por: Liguori, Maria, et al.
Publicado: (2019)

Medulla oblongata volume as a promising predictor of survival in amyotrophic lateral sclerosis
por: Milella, Giammarco, et al.
Publicado: (2022)

Cortical Thinning and Clinical Heterogeneity in Amyotrophic Lateral Sclerosis
por: Mezzapesa, Domenico Maria, et al.
Publicado: (2013)

A Clinical Scale for Rating the Severity of Bulbar Lower Motor Neuron Dysfunction in Amyotrophic Lateral Sclerosis
por: Zoccolella, Stefano, et al.
Publicado: (2023)

Riluzole and Edavarone: The Hope Against Amyotrophic Lateral Sclerosis
por: Rokade, Aditi V, et al.
Publicado: (2022)

Riluzole is associated with decreasing neuritic plaque severity in amyotrophic lateral sclerosis
por: Mazumder, Srestha, et al.
Publicado: (2022)

Riluzole prescribing, uptake and treatment discontinuation in people with amyotrophic lateral sclerosis in Scotland
por: Jayaprakash, Kiran, et al.
Publicado: (2020)

Administration of Riluzole Oral Suspension During the Different Stages of Amyotrophic Lateral Sclerosis
por: Povedano Panades, Mónica, et al.
Publicado: (2021)

Early initiation of riluzole may improve absolute survival in amyotrophic lateral sclerosis
por: Thakore, Nimish J., et al.
Publicado: (2022)

Is cerebrospinal fluid amyloid‐β42 a promising biomarker of response to nusinersen in adult spinal muscular atrophy patients?
por: Introna, Alessandro, et al.
Publicado: (2021)

Guillain‐Barré syndrome associated with inappropriate secretion of antidiuretic hormone following SARS‐CoV‐2 infection: A case‐report
por: Santoro, Carlo, et al.
Publicado: (2021)

Riluzole Selective Antioxidant Effects in Cell Models Expressing Amyotrophic Lateral Sclerosis Endophenotypes
por: Sala, Gessica, et al.
Publicado: (2019)

Dysphagia in Amyotrophic Lateral Sclerosis: Impact on Patient Behavior, Diet Adaptation, and Riluzole Management
por: Onesti, Emanuela, et al.
Publicado: (2017)

Assessment of Therapeutic Response of Edaravone and Riluzole Combination Therapy in Amyotrophic Lateral Sclerosis Patients
por: Samadhiya, Swapnil, et al.
Publicado: (2022)

Partial Block by Riluzole of Muscle Sodium Channels in Myotubes from Amyotrophic Lateral Sclerosis Patients
por: Deflorio, Cristina, et al.
Publicado: (2014)

Riluzole–Rasagiline Hybrids: Toward the Development of Multi-Target-Directed Ligands for Amyotrophic Lateral Sclerosis
por: Albertini, Claudia, et al.
Publicado: (2022)

A Randomized, Double Blind, Placebo-Controlled Trial of Pioglitazone in Combination with Riluzole in Amyotrophic Lateral Sclerosis
por: Dupuis, Luc, et al.
Publicado: (2012)

Riluzole 5 mg/mL oral suspension: for optimized drug delivery in amyotrophic lateral sclerosis
por: Dyer, Ann Margaret, et al.
Publicado: (2016)

Cerebrospinal Fluid and Clinical Profiles in Adult Type 2–3 Spinal Muscular Atrophy Patients Treated with Nusinersen: An 18-Month Single-Centre Experience
por: Milella, Giammarco, et al.
Publicado: (2021)

Riluzole: real-world evidence supports significant extension of median survival times in patients with amyotrophic lateral sclerosis
por: Hinchcliffe, Michael, et al.
Publicado: (2017)

From Riluzole to Dexpramipexole via Substituted-Benzothiazole Derivatives for Amyotrophic Lateral Sclerosis Disease Treatment: Case Studies
por: Mignani, Serge, et al.
Publicado: (2020)

In silico studies reveal structural deviations of mutant profilin-1 and interaction with riluzole and edaravone in amyotrophic lateral sclerosis
por: Sadr, Ahmad Shahir, et al.
Publicado: (2021)

Functional connectivity–based prediction of global cognition and motor function in riluzole-naive amyotrophic lateral sclerosis patients
por: Wei, Luqing, et al.
Publicado: (2022)

Repeated neurofilament light chain measurements did not capture Riluzole therapeutic effect in amyotrophic lateral sclerosis patients
por: Esselin, Florence, et al.
Publicado: (2022)

Interstitial pneumonia and other adverse events in riluzole-administered amyotrophic lateral sclerosis patients: a retrospective observational study
por: Inoue-Shibui, Aya, et al.
Publicado: (2019)

Spinal cord and brain concentrations of riluzole after oral and intrathecal administration: A potential new treatment route for amyotrophic lateral sclerosis
por: Keifer, Orion P., et al.
Publicado: (2023)

“Huoling Shengji granule” for amyotrophic lateral sclerosis: protocol for a multicenter, randomized, double-blind, riluzole parallel controlled clinical trial
por: Liu, Xiaolu, et al.
Publicado: (2023)

Riluzole and Prognostic Factors in Amyotrophic Lateral Sclerosis Long-term and Short-term Survival: A Population-Based Study of 1149 Cases in Taiwan
por: Lee, Charles Tzu-Chi, et al.
Publicado: (2013)

Long-Term Use of Riluzole Could Improve the Prognosis of Sporadic Amyotrophic Lateral Sclerosis Patients: A Real-World Cohort Study in China
por: Chen, Lu, et al.
Publicado: (2016)

Laryngeal Sensitivity in Patients with Amyotrophic Lateral Sclerosis
por: Ruoppolo, Giovanni, et al.
Publicado: (2016)

Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study
por: Fang, Ton, et al.
Publicado: (2018)

Amyotrophic lateral sclerosis
por: Wijesekera, Lokesh C, et al.
Publicado: (2009)

Amyotrophic Lateral Sclerosis: A Diet Review
por: D’Antona, Salvatore, et al.
Publicado: (2021)

Rethinking to riluzole mechanism of action: the molecular link among protein kinase CK1δ activity, TDP-43 phosphorylation, and amyotrophic lateral sclerosis pharmacological treatment
por: Bissaro, Maicol, et al.
Publicado: (2019)

Amyotrophic lateral sclerosis and neuroregeneration
Publicado: (2012)

Mimickers of Amyotrophic Lateral Sclerosis
por: Dubey, Ayush, et al.
Publicado: (2019)

Destination Amyotrophic Lateral Sclerosis
por: Keon, Matt, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_kc60srrv8mu8v7h8u5uk1pg2nu